References
- Kaspar E, Pawloski K H, Junkmann K, Schenck M. inventors; Schering AG, assignee. 17α-Acyloxyprogesterones. US patent 2,753,360. Jul 3, 1956, (Chem Abstr 1956;51:2076b,c).
- Davis M E, Wied G L. 17-α-Hydroxyprogesterone caproate: a new substance with prolonged progestational activity. A comparison with chemically pure progesterone. J Clin Endocrinol Metab 1955; 15: 923–930
- Junkmann K. Über protrahiert wirksame Gestagene. Arch Exper Path Pharmakol 1954; 223: 244
- Mavroudis K, Petsos P, Zulkifli Z, Cantrill J, Shingles C, Newman M, Mamtora H, Ratcliffe W A, Anderson D C. Trial of 17 hydroxyprogesterone caproate (Proluton depot) in women with long-standing infertility; failure of estrogen positive feedback the following cycle. Gynecol Endocrinol 1987; 1: 177–193
- Cohen M, Frank R, Desner M, Gold J. The use of a new long-acting progestational steroid (17-α-hydroxyprogesterone caproate) in the therapy of secondary amenorrhea. Am J Obstet Gynecol 1956; 76: 1103
- Sas M, Farkas M, Szegvari M. Effectiveness of 17-hydroxyprogesterone caproate (Hormofort) in clinical practice. Ther Hung 1967; 15: 21–26
- Lindsay R, Bush T L, Grady D, Speroff L, Lobo R A. Therapeutic controversy: estrogen replacement in menopause. J Clin Endocrinol Metab 1996; 81: 3829–3838
- Nilas L, Christiansen C. The pathophysiology of peri- and postmenopausal bone loss. Br J Obstet Gynaecol 1996; 96: 580–587
- Barrett-Connor E. The menopause, hormone replacement, and cardiovascular disease: the epidemiologic evidence. Maturitas 1996; 23: 227–234
- Grodstein F, Stampfer M J, Manson J E, Colditz G A, Willett W C, Rosner B, Speizer F E, Hennekens C H. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335: 453–461
- Rapp S R, Espeland M A, Shumaker S A, Henderson V W, Brunner R L, Manson J E, Gass M L, Stefanick M L, Lane D S, Hays J, Johnson K C, et al. WHIMS Investigators. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003; 289: 2663–2672
- Shumaker S A, Legault C, Rapp S R, Thal L, Wallace R B, Ockene J K, Hendrix S L, Jones B N, 3rd, Assaf A, Jackson R D, et al. WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. J Am Med Assoc 2003; 289: 2651–2662
- Gadducci A, Biglia N, Sismondi P, Genazzani A R. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol 2005; 20: 343–360
- Diamanti-Kandarakis E. Hormone replacement therapy and risk of malignancy. Curr Opin Obstet Gynecol 2004; 16: 73–78
- Lethaby A, Suckling J, Barlow D, Farquhar C M, Jepson R G, Roberts H. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004, 3: CD000402